Hideki Ikeda

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Yoshihiko Sakata, Shinya Sakata, Yuko Oya et al. · European Journal of Cancer · 2021 · 81 citations

Real-world Setting, Medicine, Pathology +8

Epidemiology and Clinical Features of Pulmonary Nontuberculous Mycobacteriosis in Nagasaki, Japan

Shotaro Ide, Shigeki Nakamura, Yoshihiro Yamamoto et al. · PLoS ONE · 2015 · 53 citations · Full text

A comparative clinical study of pneumonia by penicillin‐resistant and ‐sensitive <i>Streptococcus pneumoniae</i> in a community hospital

Hiroshi Watanabe, Satoshi Sato, Kenji Kawakami et al. · Respirology · 2000 · 39 citations

Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibility

Y Niki, Tetsuya Matsumoto, S Kohno et al. · Journal of Infection and Chemotherapy · 2009 · 39 citations · Full text

Japanese Society, Health Sciences, Antibiotics +12

Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer

Yuki Sato, Hiromitsu Sumikawa, Ryota Shibaki et al. · CHEST Journal · 2022 · 35 citations

Drug-related Pneumonitis Induced, Oncology, Perineural Invasion +10